| Harbor BioSciencs, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20100227841 | Patient populations and treatment methods - The invention provides 17α-ethynylandrost-5-ene-3β,7β,17β-triol for use in methods to treat, e.g., pre-diabetic hyperglycemia or type 2 diabetes patients having a fasting blood glucose level of at least 110 mg/dL or a post prandial glucose level of at least about 140 mg/dL an optionally a body mass index of >29.9, wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will preferably have a fasting insulin level of at least 3.5 to 4 μU/mL. | 09-09-2010 |
| 20100222315 | Patient populations and treatment methods - The invention provides 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol for use in methods to treat, e.g., hyperglycemia or diabetes patients having a body mass index of at least about 31 (≧30.5, ≧31 or ≧32), wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient will generally have a fasting insulin level of at least 4 μU/mL or another characteristic as described herein. | 09-02-2010 |
